Sugi Predict

Sugi Predict / Compounds / SCHEMBL5572945

SCHEMBL5572945

SCHEMBL5572945

Cc1c(-c2ccccc2)n(COCCO)c(=S)[nH]c1=O

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ UPP1 Q16831 1/20 0.41
▸ SIRT2 Q8IXJ6 10/20 0.40
▸ SIRT1 Q96EB6 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.38
▸ TDP1 Q9NUW8 3/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ PNP P00491 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ DRD1 P21728 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7213309 0.89 KDM4E (0.40) UPP1ALDH1A1GAAMAPT
SCHEMBL30610974 0.89 KDM4E (0.40) UPP1ALDH1A1GAAMAPT
SCHEMBL7213452 0.88 ALDH1A1 (0.37) UPP1SIRT2SIRT1ALDH1A1TDP1
SCHEMBL8760250 0.87 SIRT2 (0.47) UPP1SIRT2SIRT1ALDH1A1TDP1
SCHEMBL9353989 0.86 UPP1 (0.42) UPP1SIRT2SIRT1ALDH1A1TDP1
SCHEMBL7218829 0.86 SIRT2 (0.38) SIRT2SIRT1ALDH1A1TDP1NPSR1
SCHEMBL7219922 0.86 ALDH1A1 (0.46) SIRT2SIRT1ALDH1A1NPSR1RXFP1
SCHEMBL9353752 0.85 UPP1 (0.41) UPP1SIRT2SIRT1ALDH1A1TDP1
SCHEMBL8760939 0.85 UPP1 (0.39) UPP1SIRT2SIRT1ALDH1A1TDP1
SCHEMBL9357439 0.84 UPP1 (0.38) UPP1SIRT2SIRT1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1200097-B1 METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION VIGILENT TECHNOLOGIES (FR) 2014-01-08 — — EP claimed
US-6727059-B1 ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-04-27 — — US claimed
US-6673830-B2 COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES 2004-01-06 — — US claimed
EP-1200097-A2 METHOD FOR CONTROLLING THE FIDELITY AND THE EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION Vigilent Technologies (FR) 2002-05-02 — — EP claimed
WO-2000067698-A2 METHOD FOR CONTROLLING THE FIDELITY AND EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTABLE AS SUBSTRATES WITHOUT BLOCKING ITS ELONGATION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2000-11-16 — — WO claimed
EP-0371139-B1 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS MITSUBISHI CHEM IND (JP) 1994-10-12 — — EP claimed
US-5112835-A 6-SUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF MITSUBISHI KASEI CORPORATION (JP) 1992-05-12 — — US claimed
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 — — EP claimed
EP-0371139-A1 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS Mitsubishi Chemical Corporation (JP) 1990-06-06 — — EP claimed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 — — US disclosed
EP-1200097-B1 METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION VIGILENT TECHNOLOGIES (FR) 2014-01-08 — — EP disclosed
EP-0948256-A4 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA UNIV WASHINGTON (US) 2007-10-24 — — EP disclosed
US-7211603-B1 Enediyne compounds and methods related thereto INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2007-05-01 — — US disclosed
US-6987132-B1 Enediyne compounds and methods related thereto ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) 2006-01-17 — — US disclosed
WO-1994009781-A1 USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1994-05-11 — — WO disclosed
WO-1993016092-A1 NEW LIPOPHOSPHONIC ACID-NUCLEOSIDE CONJUGATES AND THEIR USE AS ANTIVIRAL MEDICAMENTS BOEHRINGER MANNHEIM GMBH (DE) 1993-08-19 — — WO disclosed
US-5112835-A 6-SUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF MITSUBISHI KASEI CORPORATION (JP) 1992-05-12 — — US disclosed
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 — — EP disclosed
EP-0420763-A2 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof Mitsubishi Chemical Corporation (JP) 1991-04-03 — — EP disclosed
EP-0371139-A1 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS Mitsubishi Chemical Corporation (JP) 1990-06-06 — — EP disclosed